Healthcare / Health Information ServicesTSXV
$0.09
+0.01 (+6.25%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-3.7M · quality 69.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$17M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-74.1%
↓Gross Margin
-1673.7%
↓Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-7.2%
FCF CAGR
—
FCF margin
-2252.5%
FCF / Net income
0.46x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $165403.0 · net income $-8.0M · FCF $-3.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $165403.00 | $165403.00 | $147417.00 | $161124.00 | $207093.00 |
| Net Income | $-8.0M | $-8.0M | $-6.9M | $16.1M | $-4.6M |
| EBITDA | $-5.8M | $-5.8M | $-4.2M | $4.2M | $-5.8M |
| EPS | -0.05 | -0.05 | -0.04 | 0.11 | -0.03 |
| Gross Margin | -1673.7% | -1673.7% | -872.9% | 100.0% | 73.3% |
| Operating Margin | -5407.8% | -5407.8% | -3142.3% | -2053.8% | -1804.4% |
| Net Margin | -4866.3% | -4866.3% | -4686.1% | 10016.0% | -2203.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.07 | 0.19 | -72.27 |
| Current Ratio | 0.30 | 0.30 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.7M | $-3.7M | $-4.0M | $-3.0M | $-1.4M |
| Returns | |||||
| ROE | -74.1% | -74.1% | -55.3% | 97.8% | 2248.4% |
| Valuation | |||||
| P/E | — | — | — | 0.74 | — |
| EV/EBITDA | — | — | — | 2.50 | — |
| P/B | 1.43 | 1.43 | 3.38 | 0.72 | — |
| Growth & Yield | |||||
| Revenue Growth | 12.2% | 12.2% | -8.5% | -22.2% | — |
| EPS Growth | -4.4% | -4.4% | -141.7% | 448.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-66.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.04 → -0.05
Residual
-66.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.